FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3182786185> ?p ?o ?g. }

• W3182786185 endingPage "3425" @default.
• W3182786185 startingPage "3425" @default.
• W3182786185 abstract "Abstract Background:Since their approval in 2003, Tyrosine Kinase Inhibitors (TKIs) targeting bcr-abl1 kinase activity have changed the treatment paradigm for children with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). However, off-target inhibition of kinases, such as src and c-kit, can result in impaired osteoblast function, cause an imbalance in calcium and phosphate metabolism, and result in growth impairment in children. The aim of our study was to examine growth over time in pediatric patients receiving TKIs for CML or Ph+ ALL. Description: This is a single institutional retrospective longitudinal cohort study of patients (≤ 21 years of age) diagnosed with CML or Ph+ ALL between January 2000 and December 2015 who received a TKI and had ≥ 1 year of growth data available as of May 31, 2016. Patient demographics, treatment details including the type and duration of TKI therapy and details of concomitant conventional therapy (chemotherapy and radiation) were abstracted. Growth data was abstracted from the start of TKI at yearly intervals up to a maximum of five years or age 20 and from their last available appointment. Specific variables for growth included height, height percentile, height-SDS (height - standard deviation score or z score) and BMI-SDS (body mass index - standard deviation score). Height-SDS and BMI-SDS were determined using the CDC growth chart by age and gender. Age at diagnosis was used as a surrogate for expected pubertal status: pre-pubertal (3 - 8.9 years), pubertal/peri-pubertal (9 - 15.9 years), post-pubertal (16+ years). Overall change in height-SDS / BMI-SDS from baseline to 1-year and last follow-up were compared by diagnosis, gender, and pubertal age using ANOVA. Statistical analysis was performed using SAS® v9.3 (Cary, NC). For all analyses, a p-value of Results: Our cohort included 48 patients who received a TKI (n=29 CML, n=19 Ph+ ALL) - 46% were male and 38% were non-Hispanic white. The mean age at diagnosis was 12.1 ± 3.7 years for CML and 9.0 ± 4.6 years for Ph+ ALL patients (p=0.01). As expected, mean duration of TKI treatment was longer in CML (4.3 ± 2.8 years) versus Ph+ ALL (2.7 ± 1.7 years). The average duration of follow-up was similar in both groups (CML 4.6 ± 3.54 years vs Ph+ ALL 4.1 ± 2.9 years, p=0.60). At time of diagnosis, the mean Height-SDS for the entire cohort was 0.13 ± 1.28 with no difference between patients by diagnosis (p=0.92). At one year following treatment with TKI a decrease in mean height-SDS was noted, with a more significant difference in Ph+ ALL patients (-0.54 ± 0.21) compared to CML patients (-0.18 ± 0.39) (p=0.002). This difference remained significant at last follow-up (Ph+ ALL -0.96 ± 0.70, CML -0.52 ± 0.74, p=0.05) (Figure 1). There was no significant difference in mean change in height-SDS at 1 year or last follow-up by gender. Overall, the decrease in height-SDS at 1 year was most significant in the pre-pubertal age group (-0.51 ± 0.27) as compared to pubertal/peri-pubertal and post-pubertal groups (-0.26 ± 0.46 and -0.10 ± 0.24 respectively; p=0.04). BMI-SDS at baseline did not differ by diagnosis but did show a significant decrease at one year in Ph+ ALL versus CML patients (-0.18 ± 0.65 and 0.39 ± 0.54 respectively, p=0.003); this stabilized at the time of last follow up (-0.01 ± 0.75 and 0.38 ± 0.80 respectively, p=0.11). Conclusions: Our data underscores the concern of growth disturbances following prolonged TKI exposure in children, the role of exposure relative to pubertal change in bone growth, and the need for understanding off-target mechanisms in childhood survivors. Stabilization of BMI-SDS at the end of follow up with accompanying drop in mean height-SDS points to a mechanism of growth disturbance beyond nutritional deficiencies. This large pediatric cohort treated with TKIs is the first to include Ph+ ALL patients who were younger at onset of TKI treatment, and more likely to be pre/peripubertal at the start TKI exposure. Future directions will focus on a prospective study of musculoskeletal and other organ toxicities in patients treated with TKIs in childhood. Download : Download high-res image (121KB) Download : Download full-size image Disclosures No relevant conflicts of interest to declare." @default.
• W3182786185 created "2021-07-19" @default.
• W3182786185 creator A5008956076 @default.
• W3182786185 creator A5036356438 @default.
• W3182786185 creator A5046397950 @default.
• W3182786185 creator A5047469126 @default.
• W3182786185 creator A5060453219 @default.
• W3182786185 creator A5071691754 @default.
• W3182786185 creator A5075022242 @default.
• W3182786185 creator A5078950754 @default.
• W3182786185 creator A5081473405 @default.
• W3182786185 date "2017-12-07" @default.
• W3182786185 modified "2023-09-26" @default.
• W3182786185 title "Growth Disturbances in Pediatric Patients Receiving Long-Term Tyrosine Kinase Inhibitor Therapy" @default.
• W3182786185 doi "https://doi.org/10.1182/blood.v130.suppl_1.3425.3425" @default.
• W3182786185 hasPublicationYear "2017" @default.
• W3182786185 type Work @default.
• W3182786185 sameAs 3182786185 @default.
• W3182786185 citedByCount "0" @default.
• W3182786185 crossrefType "journal-article" @default.
• W3182786185 hasAuthorship W3182786185A5008956076 @default.
• W3182786185 hasAuthorship W3182786185A5036356438 @default.
• W3182786185 hasAuthorship W3182786185A5046397950 @default.
• W3182786185 hasAuthorship W3182786185A5047469126 @default.
• W3182786185 hasAuthorship W3182786185A5060453219 @default.
• W3182786185 hasAuthorship W3182786185A5071691754 @default.
• W3182786185 hasAuthorship W3182786185A5075022242 @default.
• W3182786185 hasAuthorship W3182786185A5078950754 @default.
• W3182786185 hasAuthorship W3182786185A5081473405 @default.
• W3182786185 hasConcept C104317684 @default.
• W3182786185 hasConcept C126322002 @default.
• W3182786185 hasConcept C138626823 @default.
• W3182786185 hasConcept C187212893 @default.
• W3182786185 hasConcept C2777413986 @default.
• W3182786185 hasConcept C2777583451 @default.
• W3182786185 hasConcept C2778729363 @default.
• W3182786185 hasConcept C2778904597 @default.
• W3182786185 hasConcept C2779384505 @default.
• W3182786185 hasConcept C2780221984 @default.
• W3182786185 hasConcept C55493867 @default.
• W3182786185 hasConcept C71924100 @default.
• W3182786185 hasConcept C72563966 @default.
• W3182786185 hasConcept C86803240 @default.
• W3182786185 hasConceptScore W3182786185C104317684 @default.
• W3182786185 hasConceptScore W3182786185C126322002 @default.
• W3182786185 hasConceptScore W3182786185C138626823 @default.
• W3182786185 hasConceptScore W3182786185C187212893 @default.
• W3182786185 hasConceptScore W3182786185C2777413986 @default.
• W3182786185 hasConceptScore W3182786185C2777583451 @default.
• W3182786185 hasConceptScore W3182786185C2778729363 @default.
• W3182786185 hasConceptScore W3182786185C2778904597 @default.
• W3182786185 hasConceptScore W3182786185C2779384505 @default.
• W3182786185 hasConceptScore W3182786185C2780221984 @default.
• W3182786185 hasConceptScore W3182786185C55493867 @default.
• W3182786185 hasConceptScore W3182786185C71924100 @default.
• W3182786185 hasConceptScore W3182786185C72563966 @default.
• W3182786185 hasConceptScore W3182786185C86803240 @default.
• W3182786185 hasLocation W31827861851 @default.
• W3182786185 hasOpenAccess W3182786185 @default.
• W3182786185 hasPrimaryLocation W31827861851 @default.
• W3182786185 hasRelatedWork W1966273346 @default.
• W3182786185 hasRelatedWork W1979438636 @default.
• W3182786185 hasRelatedWork W2060509601 @default.
• W3182786185 hasRelatedWork W2088881958 @default.
• W3182786185 hasRelatedWork W2418238198 @default.
• W3182786185 hasRelatedWork W2420759594 @default.
• W3182786185 hasRelatedWork W2470572417 @default.
• W3182786185 hasRelatedWork W2548958077 @default.
• W3182786185 hasRelatedWork W2566684432 @default.
• W3182786185 hasRelatedWork W2576175308 @default.
• W3182786185 hasRelatedWork W2772175690 @default.
• W3182786185 hasRelatedWork W2899681234 @default.
• W3182786185 hasRelatedWork W2909090656 @default.
• W3182786185 hasRelatedWork W2959829984 @default.
• W3182786185 hasRelatedWork W2965266319 @default.
• W3182786185 hasRelatedWork W2979780327 @default.
• W3182786185 hasRelatedWork W3008633751 @default.
• W3182786185 hasRelatedWork W3088935168 @default.
• W3182786185 hasRelatedWork W3116208693 @default.
• W3182786185 hasRelatedWork W2592845458 @default.
• W3182786185 hasVolume "130" @default.
• W3182786185 isParatext "false" @default.
• W3182786185 isRetracted "false" @default.
• W3182786185 magId "3182786185" @default.
• W3182786185 workType "article" @default.